Not Yet Enrolling

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

J2T-MC-KGBW -

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis.

Trial Summary

Age Range
≥12 years
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
lebrikizumab, topical corticosteroid
Could I receive a Placebo?
Yes
Enrollment Goal
430
Trial Dates
May 6, 2024 - Nov 2026
How long will I be in the trial?
The study will last approximately 62 weeks.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have chronic AD that has been present for ≥1 year before the screening period or have chronic eczema and meet the AAD criteria

  • Have moderate-to-severe AD, including all of the following at the baseline: EASI score ≥16,IGA score ≥3 (scale of 0 to 4) , ≥10% BSA of AD involvement

Participants Must Not:

  • Have a history of anaphylaxis or uncontrolled chronic disease that might require bursts of oral corticosteroids

  • Have a current or recent acute, active infection. For at least 30 days before screening and up to the randomization, participants must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources